RegulatoryCompany release

Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045

🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Thu 19 Nov 2026

The USPTO has granted Allarity Therapeutics a patent with 36 allowed claims covering twice-daily oral stenoparib in advanced ovarian cancer and other solid tumours.

Allarity Therapeutics has been granted U.S. Patent No. 12,806,205 for stenoparib, its PARP/tankyrase inhibitor. The company announced the grant on 18 November 2026. The patent contains 36 allowed claims on twice-daily oral dosing and on methods of treating advanced ovarian cancer and other solid tumours.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Allarity Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Allarity Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.